Ginkgo Bioworks Holdings, Inc. (NYSE:DNA - Get Free Report) traded up 8.8% during mid-day trading on Friday . The stock traded as high as $14.58 and last traded at $14.74. 625,008 shares were traded during mid-day trading, a decline of 59% from the average session volume of 1,532,414 shares. The stock had previously closed at $13.55.
Ginkgo Bioworks Trading Down 6.4 %
The company's fifty day moving average price is $11.34. The stock has a market cap of $792.36 million, a P/E ratio of -1.05 and a beta of 1.16.
Hedge Funds Weigh In On Ginkgo Bioworks
Hedge funds have recently modified their holdings of the company. SBI Securities Co. Ltd. purchased a new stake in shares of Ginkgo Bioworks during the fourth quarter valued at approximately $29,000. KBC Group NV purchased a new stake in shares of Ginkgo Bioworks during the 4th quarter valued at $31,000. KLP Kapitalforvaltning AS bought a new stake in shares of Ginkgo Bioworks during the 4th quarter worth $46,000. Mercer Global Advisors Inc. ADV purchased a new position in shares of Ginkgo Bioworks in the 4th quarter worth about $116,000. Finally, Palumbo Wealth Management LLC bought a new position in Ginkgo Bioworks during the fourth quarter valued at about $144,000. Institutional investors own 78.63% of the company's stock.
About Ginkgo Bioworks
(
Get Free Report)
Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.
Read More
Before you consider Ginkgo Bioworks, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ginkgo Bioworks wasn't on the list.
While Ginkgo Bioworks currently has a "Reduce" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
